Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma

This study has been completed.

Study NCT00179673 Information provided by Celgene Corporation

First Received: September 10, 2005 Last Updated: November 30, 2006 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	November 2006
Estimated Primary Completion Date:	No date given